NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
Clinical Trials
41 trialsNCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05233397 2026-03-02
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT03970226 2026-02-17
Tocilizumab in Children With ACP
University of Colorado, Denver
Phase EARLY_PHASE1 Active not recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT04375228 2026-02-06
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
Phase 2 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT04691817 2026-01-07
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT06043674 2026-01-07
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06251076 2025-12-10
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
Phase 4 Recruiting
NCT04007029 2025-09-05
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04377659 2025-05-28
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT06016179 2025-05-22
RIOT2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT03821246 2025-05-15
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
University of California, San Francisco
Phase 2 Recruiting
NCT03434730 2025-04-22
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03708224 2025-01-28
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Phase 2 Recruiting
NCT05333302 2024-08-28
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase 1 Recruiting
NCT05716035 2024-01-22
tMG-E
Tang-Du Hospital
Phase 2/3 Unknown
NCT05833763 2024-01-08
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
Phase 2 Recruiting
NCT02767557 2023-09-22
PACTO
Herlev Hospital
Phase 2 Completed
NCT05855122 2023-06-02
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT04547062 2023-04-28
Tocilam
Nantes University Hospital
Phase 1 Completed
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05730777 2023-02-16
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
Peking University Third Hospital
Phase 4 Unknown
NCT04871854 2022-11-01
Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
Beni-Suef University
Phase 2 Completed
NCT04258150 2022-03-31
TRIPPLE-R
Herlev Hospital
Phase 2 Terminated
NCT03588936 2021-10-11
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
Phase 1 Terminated
NCT03135171 2021-09-10
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02906371 2021-07-02
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
University of Pennsylvania
Phase 1 Completed
NCT04115423 2020-09-10
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
Sungkyunkwan University
Unknown
NCT04361552 2020-06-18
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
Phase 3 Withdrawn
NCT03601611 2020-04-21
COLAR
Herlev Hospital
Phase NA Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT02057770 2018-10-12
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1 Terminated
NCT02997956 2017-04-25
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT02447055 2016-07-12
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Withdrawn
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed
NCT00630292 2010-05-18
Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors
University of North Carolina, Chapel Hill
Phase NA Terminated